Doehn C, Bögemann M, Grünwald V, Welslau M, Bedke J, Schostak M, Wolf T, Ehneß R, Degenkolbe E, Witecy S, Goebell P (2022)
Publication Type: Journal article
Publication year: 2022
Book Volume: 14
Article Number: 5486
Journal Issue: 22
The approval of tyrosine kinase inhibitors and checkpoint inhibitors represented a remarkable progression in the therapeutic landscape for the treatment of metastatic renal cell carcinoma (mRCC). Yet, in the ever-evolving landscape of mRCC treatment, real-world data on these agents, including pazopanib, are scarce. The non-interventional PAZOREAL study investigated the effectiveness and safety of pazopanib (first-line), nivolumab (second-line), and everolimus (second- and third-line) in a real-life setting. The multicentric study included 376 mRCC patients who received first-line treatment with pazopanib and assessed time on the drug (primary endpoint), overall survival, best responses, disease control rates, as well as safety signals and health-related quality of life. The median overall time on the drug was 10.0 months, with first-line pazopanib having a median time on drug of 6.3 months. The median overall survival was 35.9 months. The disease control rate for first-line pazopanib was 56.9%. No new safety signals were detected. PAZOREAL provides valuable real-world data for first-line treatment with pazopanib.
APA:
Doehn, C., Bögemann, M., Grünwald, V., Welslau, M., Bedke, J., Schostak, M.,... Goebell, P. (2022). The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape. Cancers, 14(22). https://doi.org/10.3390/cancers14225486
MLA:
Doehn, Christian, et al. "The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape." Cancers 14.22 (2022).
BibTeX: Download